Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Akums Drugs and Pharmaceuticals has informed the exchange that it has submitted its financial results for the quarter and full year ended March 31, 2025. The company is an Indian pharmaceutical manufacturer focused on formulations and contract manufacturing. The filing itself is a procedural intimation and does not include the detailed numbers, which would be found in the attached results document. Investors will need to review the actual results PDF to assess revenue, profit, margins, and other key metrics. No specific figures, growth rates, or auditor observations are disclosed in this notice.
This is a routine filing intimation and is unlikely to move the stock on its own; the actual market reaction will depend on the numbers in the detailed results, especially revenue growth, profit margins, and any forward guidance.